Head to Head Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. Alliqua BioMedical (OTCMKTS:ADYX)

Alliqua BioMedical (OTCMKTS:ADYX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares Alliqua BioMedical and Jazz Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alliqua BioMedical	N/A	N/A	N/A
Jazz Pharmaceuticals	-9.91%	5.02%	1.73%

Valuation and Earnings

This table compares Alliqua BioMedical and Jazz Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alliqua BioMedical	N/A	N/A	N/A	N/A	N/A
Jazz Pharmaceuticals	$4.16 billion	2.00	$560.12 million	($6.07)	-22.59

Jazz Pharmaceuticals has higher revenue and earnings than Alliqua BioMedical.

Institutional and Insider Ownership

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 17.4% of Alliqua BioMedical shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Alliqua BioMedical and Jazz Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alliqua BioMedical	0	0	0	0	0.00
Jazz Pharmaceuticals	1	2	13	0	2.75

Jazz Pharmaceuticals has a consensus price target of $178.50, indicating a potential upside of 30.19%. Given Jazz Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Alliqua BioMedical.

Summary

Jazz Pharmaceuticals beats Alliqua BioMedical on 7 of the 9 factors compared between the two stocks.

About Alliqua BioMedical

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson’s disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.